WeightWatchers is struggling in the weight loss drug era — and now the CEO is out
International said Friday that CEO Sima Sistani is stepping down immediately. She will be replaced by Tara Comonte, a board member and the former CEO of Shake Shack (SHAK), who was appointed as interim chief executive effective immediately.
11hon MSN
Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.
The Senate investigation showed Americans pay $1,349 a month for the weight-loss drug Wegovy, which is priced at $92 in the United Kingdom.
Patients on semaglutide, the active ingredient in Ozempic and the weight-loss drug Wegovy, were less than half as likely to overdose.
Novo Nordisk CEO Lars Fruergaard Jørgensen is testifying before the Senate Health, Education, Labor and Pension committee on ...
2don MSN
Michelle Ross, StemPoint Capital CIO and Novo Nordisk shareholder, joins CNBC's 'Closing Bell' to discuss the criticism Novo ...
To fight off compounding pharmacies, Eli Lilly wants access to medical records of patients who used copycat products.
In a phase 1 trial, Novo Nordisk's experimental obesity drug amycretin led to up to 13% weight loss in just three months.
Shares of BioAge Labs opened 25% above their initial public offering price on Thursday in a strong debut for the weight-loss drug developer against the backdrop of surging investor enthusiasm.
Thousands of plaintiffs have sued Ozempic manufacturers for failing to warn them about the risk of stomach paralysis.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback